These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18405184)

  • 1. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
    Bagot M
    Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
    [No Abstract]   [Full Text] [Related]  

  • 2. Bexarotene monotherapy for patients with refractory Sézary syndrome.
    Staib G; Scharffetter-Kochanek K
    Dermatol Clin; 2008 Jan; 26 Suppl 1():61-3. PubMed ID: 18405190
    [No Abstract]   [Full Text] [Related]  

  • 3. Bexarotene salvage therapy in a patient with refractory erythrodermic mycosis fungoides after failure on interferon/PUVA and methotrexate.
    Dalle S; Thomas L
    Dermatol Clin; 2008 Jan; 26 Suppl 1():39-41. PubMed ID: 18405186
    [No Abstract]   [Full Text] [Related]  

  • 4. Bexarotene combination therapy for patients with Sézary syndrome.
    Ranki A
    Dermatol Clin; 2008 Jan; 26 Suppl 1():55-7. PubMed ID: 18405189
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
    el-Azhary RA; Bouwhuis SA
    Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
    Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
    J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute hyperkeratotic and desquamative reaction in a patient with Sézary syndrome treated with bexarotene.
    Bagazgoitia L; Pérez-Carmona L; Ríos L; Muñoz E; Harto A; Jaén P
    J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):389-90. PubMed ID: 18269619
    [No Abstract]   [Full Text] [Related]  

  • 8. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
    Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
    Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a patient with Sézary syndrome treated by methotrexate.
    Ingen-Housz-Oro S; Ortonne N; Cordel N; Moroch J; Do-Pham G; Delfau MH; Haioun C; Chosidow O
    Br J Dermatol; 2016 Aug; 175(2):430-3. PubMed ID: 27031298
    [No Abstract]   [Full Text] [Related]  

  • 10. Disappearance of seborrheic keratoses following treatment with methotrexate.
    Seyfer SJ; Duvic M
    Cutis; 2013 Jul; 92(1):E2-3. PubMed ID: 23961531
    [No Abstract]   [Full Text] [Related]  

  • 11. Bexarotene monotherapy for patients with refractory early stage mycosis fungoides.
    Stein A
    Dermatol Clin; 2008 Jan; 26 Suppl 1():67-70. PubMed ID: 18405191
    [No Abstract]   [Full Text] [Related]  

  • 12. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
    Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
    J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
    [No Abstract]   [Full Text] [Related]  

  • 13. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
    McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
    Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody).
    Osborne GE; Pagliuca A; Ho A; du Vivier AW
    Br J Dermatol; 2006 Sep; 155(3):617-20. PubMed ID: 16911291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
    Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
    Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of Sézary syndrome with lymphomatous transformation to large cell lymphoma with fludarabine phosphate.
    Nikko AP; RutherFord CJ; Pandya AG
    Arch Dermatol; 1996 Aug; 132(8):978-9. PubMed ID: 8712858
    [No Abstract]   [Full Text] [Related]  

  • 17. Sézary syndrome associated with granulomatous lesions during treatment with bexarotene.
    Ruiz-de-Casas A; Carrizosa-Esquivel A; Herrera-Saval A; Rios-Martín JJ; Camacho F
    Br J Dermatol; 2006 Feb; 154(2):372-4. PubMed ID: 16433814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of late-stage Sézary syndrome with 2-Chlorodeoxyadenosine.
    Bouwhuis SA; el-Azhary RA; McEvoy MT; Gibson LE; Habermann TM; Witzig TE; Pittelkow MR
    Int J Dermatol; 2002 Jun; 41(6):352-6. PubMed ID: 12100691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome.
    McGinnis KS; Ubriani R; Newton S; Junkins-Hopkins JM; Vittorio CC; Kim EJ; Wysocka M; Rook AH
    Arch Dermatol; 2005 Sep; 141(9):1176-8. PubMed ID: 16172331
    [No Abstract]   [Full Text] [Related]  

  • 20. Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol.
    Arulogun S; Prince HM; Gambell P; Lade S; Ryan G; Eaton E; McCormack C
    J Am Acad Dermatol; 2008 Oct; 59(4):589-95. PubMed ID: 18656282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.